Ingyenes szállítás a Packetával, 19 990 Ft feletti vásárlás esetén
Posta 1 795 Ft DPD 1 995 Ft PostaPont / Csomagautomata 1 690 Ft Postán 1 690 Ft GLS futár 1 590 Ft Packeta 990 Ft GLS pont 1 390 Ft

Optimizing the "Drug-Like" Properties of Leads in Drug Discovery

Nyelv AngolAngol
Könyv Kemény kötésű
Könyv Optimizing the "Drug-Like" Properties of Leads in Drug Discovery Ronald T. Borchardt
Libristo kód: 02223364
Kiadó Springer-Verlag New York Inc., augusztus 2006
Traditionally, incorporating optimal drug-like properties into a structural lead was not considered... Teljes leírás
? points 603 b
97 070 Ft
Beszállítói készleten alacsony példányszámban Küldés 10-15 napon belül

30 nap a termék visszaküldésére


Ezt is ajánljuk


Lonely Planet Austria Anthony Haywood et al / Puha kötésű
common.buy 12 678 Ft
Issues in Mathematics Teaching Peter Gates / Puha kötésű
common.buy 21 623 Ft
In Search of More Solutions J Taylor / Puha kötésű
common.buy 12 580 Ft

Traditionally, incorporating optimal drug-like properties into a structural lead was not considered by medicinal chemists to be their responsibility. Instead, medicinal chemists felt that the undesirable drug-like properties in their drug candidates would be fixed by preclinical development scientists. However, that view has changed in the past 5 10 years, resulting in another significant paradigm shift in drug discovery. The most significant aspect of this latest paradigm shift is the recognition by medicinal chemists that the drug-like properties of structural hits, structural leads, and drug candidates are intrinsic properties of the molecules and that it is the responsibility of the medicinal chemist to optimize not only the pharmacological properties but also the drug-like properties of these molecules. Therefore, assessment of these drug-like properties is now done early in the drug discovery process on structural hits and structural leads as well as the design of screening libraries. Optimization of these drug-like properties is done through an iterative process in close collaboration with preclinical development scientists. This process is analogous to the process used by the medicinal chemist to characterize and optimize the pharmacological activity of their structural hits, leads and drug candidates.Recognizing these changes in the paradigm by which drugs are discovered, the American Association of Pharmaceutical Scientists (AAPS) has recently organized and sponsored two focused workshops in the area of profiling drug-like properties during drug discovery.The first workshop, entitled "Pharmaceutical Profiling in Drug Discovery for Lead Selection", took place in Whippany, NJ on May 19-21, 2003. This workshop, which was co-sponsored by the American Chemical Society-Medicinal Chemistry Division and the Society for Biomolecular Screening, was focused on prediction, measurement, and utilization of drug-like properties during lead selection. From this workshop arose the book entitled Pharmaceutical Profiling in Drug discovery for Lead Selection, which was edited by Ronald T. Borchardt, Edward H. Kerns, Christopher A. Lipinski, Dhiren R. Thakker and Binghe Wang and published by AAPS Press (Arlington, VA) in 2004.The second workshop entitled "Optimizing the Drug-Like Properties of Leads in Drug Discovery" took place in Parsippany, NJ on September 19-22, 2004. This workshop, which was co-sponsored by the American Chemical Society-Medicinal Chemistry Division, American Chemical Society-North Jersey Section, American Society for Clinical Pharmacology and Therapeutics, European Federation for Pharmaceutical Sciences, International Society for the study of Xenobiotics, and the Society of Toxicology, was focused on the optimization of the drug-like properties of leads in drug discovery. If the strategies and the methodologies presented at this workshop were to be adopted by pharmaceutical and biotechnology companies, it is the belief of the workshop s organizers that more higher quality drug candidates would be advancing into preclinical and clinical development resulting in more efficacious and safer drugs.Traditionally, incorporating optimal drug-like properties into a structural lead was not considered by medicinal chemists to be their responsibility. Instead, medicinal chemists felt that the undesirable drug-like properties in their drug candidates would be fixed by preclinical development scientists. However, that view has changed in the past 5 10 years, resulting in another significant paradigm shift in drug discovery. The most significant aspect of this latest paradigm shift is the recognition by medicinal chemists that the drug-like properties of structural hits, structural leads, and drug candidates are intrinsic properties of the molecules and that it is the responsibility of the medicinal chemist to optimize not only the pharmacological properties but also the drug-like properties of these molecules. Therefore, assessment of these drug-like properties is now done early in the drug discovery process on structural hits and structural leads as well as the design of screening libraries. Optimization of these drug-like properties is done through an iterative process in close collaboration with preclinical development scientists. This process is analogous to the process used by the medicinal chemist to characterize and optimize the pharmacological activity of their structural hits, leads and drug candidates.§Recognizing these changes in the paradigm by which drugs are discovered, the American Association of Pharmaceutical Scientists (AAPS) has recently organized and sponsored two focused workshops in the area of profiling drug-like properties during drug discovery. §The first workshop, entitled "Pharmaceutical Profiling in Drug Discovery for Lead Selection", took place in Whippany, NJ on May 19-21, 2003. This workshop, which was co-sponsored by the American Chemical Society-Medicinal Chemistry Division and the Society for Biomolecular Screening, was focused on prediction, measurement, and utilization of drug-like properties during lead selection. From this workshop arose the book entitled Pharmaceutical Profiling in Drug discovery for Lead Selection, which was edited by Ronald T. Borchardt, Edward H. Kerns, Christopher A. Lipinski, Dhiren R. Thakker and Binghe Wang and published by AAPS Press (Arlington, VA) in 2004. §The second workshop entitled "Optimizing the Drug-Like Properties of Leads in Drug Discovery" took place in Parsippany, NJ on September 19-22, 2004. This workshop, which was co-sponsored by the American Chemical Society-Medicinal Chemistry Division, American Chemical Society-North Jersey Section, American Society for Clinical Pharmacology and Therapeutics, European Federation for Pharmaceutical Sciences, International Society for the study of Xenobiotics, and the Society of Toxicology, was focused on the optimization of the drug-like properties of leads in drug discovery. If the strategies and the methodologies presented at this workshop were to be adopted by pharmaceutical and biotechnology companies, it is the belief of the workshop s organizers that more higher quality drug candidates would be advancing into preclinical and clinical development resulting in more efficacious and safer drugs.

Információ a könyvről

Teljes megnevezés Optimizing the "Drug-Like" Properties of Leads in Drug Discovery
Nyelv Angol
Kötés Könyv - Kemény kötésű
Kiadás éve 2006
Oldalszám 512
EAN 9780387340562
ISBN 0387340564
Libristo kód 02223364
Súly 1172
Méretek 178 x 254 x 33
Ajándékozza oda ezt a könyvet még ma
Nagyon egyszerű
1 Tegye a kosárba könyvet, és válassza ki a kiszállítás ajándékként opciót 2 Rögtön küldjük Önnek az utalványt 3 A könyv megérkezik a megajándékozott címére

Belépés

Bejelentkezés a saját fiókba. Még nincs Libristo fiókja? Hozza létre most!

 
kötelező
kötelező

Nincs fiókja? Szerezze meg a Libristo fiók kedvezményeit!

A Libristo fióknak köszönhetően mindent a felügyelete alatt tarthat.

Libristo fiók létrehozása